For patients whose tumors have a high PD-L1 tumor proportion score (TPS) of greater than or equal to 50%, PD-(L)1 monotherapy represents one of the approved options which has the advantage of sparing the side effects of platinum doublet chemotherapy.1, 2, 3, 4 For patients with negative (<1%) or low (1%–49%) PD-L1 expression, a combination of platinum doublet chemotherapy and a PD-(L)1 inhibitor is generally favored, given that PD-(L)1 monotherapy may not be as effective in this patient population.2 Here, CD274 is linked to neoplasm.